Navigation Links
AutoImmune Inc. Reports 2008 Second Quarter Financial Results
Date:8/7/2008

PASADENA, Calif., Aug. 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Pink Sheets: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008, compared with a net loss of $62,000, or break even per share basic and diluted, for the three months ended June 30, 2007. For the six months ended June 30, 2008, the net loss was $193,000, or $0.01 per share basic and diluted, compared with net loss of $54,000, or break even per share basic and diluted for the same period in 2007. As of June 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC met our expectations during the second quarter." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS sublicensed its rights in this product to Eli Lilly and Company and subsequently stated that the only results they expect to release in 2008 from an upcoming interim analysis on the first 200 patients in its pivotal phase II/III trial evaluating MBP8298 for treatment of secondary progressive multiple sclerosis will be those related to safety and/or futility. A full analysis of the trial data should be available during the second half of 2009.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release tha
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. Isis Reports Financial Results and Highlights for Second Quarter of 2008
6. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. Caliper Life Sciences Reports Second Quarter 2008 Results
9. Watson Pharmaceuticals Reports Second Quarter 2008 Results
10. EntreMed Reports Second Quarter 2008 Financial Results
11. Transgenomic Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO ... Joseph as Chief Legal Officer.  Mr. Joseph brings ... and has worked in both public and private companies, ... (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ) "Don ... general counsel and senior executive and his knowledge and ...
(Date:6/17/2013)... 2013 zuChem Inc., a leading ... nutrition, announced today that the United States Patent ... - US 8,367,346 entitled “Methods for Production of ... for producing D-Mannitol." These two patents expand zuChem's ... food sweetener products from abundant, renewable feedstocks. ...
(Date:6/17/2013)... NY (PRWEB) June 17, 2013 With the ... the launch of the Chief Medical Officer Summit for Emerging ... will take place in San Francisco on November 4-5, ... For the first time, West Coast Chief Medical Officers at ... Dr. Elizabeth Stoner, Managing Director of MPM Capital. Valerie Bowling, ...
(Date:6/17/2013)... The ALS Therapy Development Institute (ALS TDI) will hold ... event on July 19-21, 2013. The Tri-State Trek is a three-day, ... to Greenwich, CT with the mission to ... disease). (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO ) ... passes through 46 communities and includes 12 rest stops, ...
Breaking Biology Technology:KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4zuChem Receives Two Polyol Patents 2Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21 2ALS TDI Tri-State Trek Charity Bike Ride to Take Place July 19-21 3
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 2011 Asmacure Ltee, a clinical-stage biopharmaceutical ... for the treatment of asthma and other inflammatory diseases, ... chief executive officer.  With a solid foundation established at ... progresses its lead compound, a potential new treatment for ...
... KONG, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... plan to release financial results for the fourth quarter and ... 2011, after market close in the US.   ... ET on Monday, June 13, 2011 to discuss its financial ...
Cached Biology Technology:EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:6/14/2013)... World War II soldiers, "The White Cliffs of Dover" ... times. To geographers, the white cliffs mark the point ... scientists, the white cliffs are towering structures made of ... alga known as Emiliania huxleyi . "Ehux" is ... Even though the process by which the alga,s "armor" ...
(Date:6/14/2013)... OttawaJune 14, 2013Here,s a good reason to pay ... has published a paper from Ottawa researchers today, ... in the fight against cancer. The technique predicts ... cancer-killing, oncolytic viruses to overcome the natural defences ... infection. , "Oncolytic viruses are special in ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Using math to kill cancer cells 22013 World Cultural Council awards 22013 World Cultural Council awards 3
... major new review of scientific knowledge on kava a ... with calming effects has left unsolved the mystery of ... in the United States, Europe, and other Western cultures sometimes ... Chemical Research in Toxicology . Line Olsen and colleagues ...
... release is available in German and Spanish ... in Chile pose a higher threat to its neighbour, Argentina, ... University of Concepcin in Chile and the Helmholtz Centre for ... In particular, 22 non-native species which occur in Chile on ...
... , This release is available in German ... protects them against diseases. The early detection of pathogens and ... work as a protective shield. However, the pathogens that cause ... suppress the natural cell wall reaction in plants. "One particularly ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3TUM researchers discover a new switch in resistance to plant diseases 2
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
NAP-2 (5C7)...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: